Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$13.58 - $17.36 $182,515 - $233,318
13,440 Added 29.34%
59,247 $931,000
Q4 2023

Feb 13, 2024

BUY
$10.11 - $16.54 $463,108 - $757,647
45,807 New
45,807 $738,000
Q3 2023

Nov 13, 2023

BUY
$12.46 - $15.48 $42,725 - $53,080
3,429 Added 22.45%
18,700 $237,000
Q2 2023

Aug 14, 2023

BUY
$13.28 - $15.96 $743 - $893
56 Added 0.37%
15,271 $215,000
Q1 2023

May 11, 2023

BUY
$14.26 - $22.1 $46,730 - $72,421
3,277 Added 27.45%
15,215 $235,000
Q4 2022

Feb 13, 2023

BUY
$14.85 - $19.04 $177,279 - $227,299
11,938 New
11,938 $195,000
Q1 2022

May 11, 2022

SELL
$6.87 - $11.11 $2.09 Million - $3.38 Million
-304,451 Closed
0 $0
Q4 2021

Feb 07, 2022

BUY
$7.7 - $37.13 $74,289 - $358,230
9,648 Added 3.27%
304,451 $2.97 Million
Q3 2021

Nov 10, 2021

SELL
$26.46 - $37.15 $10,531 - $14,785
-398 Reduced 0.13%
294,803 $10 Million
Q2 2021

Aug 05, 2021

BUY
$32.73 - $47.95 $1.04 Million - $1.53 Million
31,842 Added 12.09%
295,201 $10.8 Million
Q1 2021

May 14, 2021

BUY
$40.39 - $56.73 $1.96 Million - $2.75 Million
48,557 Added 22.61%
263,359 $11.8 Million
Q4 2020

Feb 12, 2021

BUY
$51.77 - $66.18 $668,143 - $854,119
12,906 Added 6.39%
214,802 $12.3 Million
Q3 2020

Nov 13, 2020

BUY
$43.8 - $58.16 $1.96 Million - $2.6 Million
44,782 Added 28.5%
201,896 $10.4 Million
Q2 2020

Aug 13, 2020

BUY
$37.05 - $65.03 $3.2 Million - $5.62 Million
86,366 Added 122.08%
157,114 $9.38 Million
Q1 2020

May 14, 2020

BUY
$33.63 - $69.4 $2.38 Million - $4.91 Million
70,748 New
70,748 $2.91 Million

Others Institutions Holding DCPH

About Deciphera Pharmaceuticals, Inc.


  • Ticker DCPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,822,100
  • Description
  • Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gas...
More about DCPH
Track This Portfolio

Track American Century Companies Inc Portfolio

Follow American Century Companies Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

News

Stay updated on American Century Companies Inc with notifications on news.